Last issue covered Japan - the deaths, the regulatory gaps, the distance between a notification requirement and actual oversight. This issue covers the American version. No deaths that we know of. But a documented pattern, now active in multiple courts, of vulnerable patients being walked into expensive treatment packages for conditions the treatments have not been approved to treat, without being told that fact, and leaving with financing agreements they did not fully understand. The mechanism is different, but the underlying condition is the same.
THE RADAR
South Korea just built the infrastructure that legitimate iPSC therapy requires
In late March, South Korea's national health agency established 18 clinical-grade iPSC lines under good manufacturing practice conditions and began distributing them to domestic research institutions and biotech companies. One of those lines has been developed into a Master Cell Bank - a standardised repository capable of supplying consistent, large-volume cell stocks for clinical research. The cells were produced primarily from type O blood to reduce rejection risk. This is foundational work, not a treatment: the kind of infrastructure that legitimate iPSC therapy actually requires, built to reduce the cost and time barriers that make iPSC development prohibitive for smaller research programmes.
Japan's regulatory story has a second side
Issue 5 covered the deaths from unregulated treatments in Japan's private clinic market. A separate development from February deserves a brief note: a Japanese government advisory panel endorsed two iPSC-based products — one targeting heart disease, one targeting Parkinson's — for progression toward conditional approval through Japan's formal regulatory pathway. This is the same country, a different track entirely. Japan's conditional approval system has real problems, documented in the previous issue. It is also producing genuinely evaluated iPSC candidates. Both things are true at once, and conflating them, in either direction, gets the story wrong.
Inside the sales appointment: how a national clinic chain turned regenerative medicine into a closing room
The plaintiff was 87 years old. She had chronic knee pain. She went to a consultation at a regenerative medicine clinic to find out about her options. She left with a financing agreement for treatments she had not come in seeking, covering body parts she had not complained about, totalling a sum she had not anticipated. According to the lawsuit now active in Florida, she was not told that the treatments were not approved by the FDA.
This is not an isolated complaint. It is a documented pattern at a clinic chain operating nearly 200 locations across the United States, now facing class action litigation in multiple states. The lawsuits allege the same sequence of events across dozens of patients: a consultation that functions as a sales presentation, a recommendation to treat more than the patient came in for, financing arranged through third-party lenders on the spot, and a consistent failure to disclose that the treatments (PRP injections and bone marrow concentrate for joint pain) do not hold FDA approval for the conditions being marketed.
The FDA has issued prior warnings about this category of unapproved regenerative treatment. No enforcement action has been taken against this specific chain. The courts are moving where the regulator has not.
It is worth being precise about what the lawsuits allege and what they do not. These are civil proceedings, not findings of liability. The company has not been found guilty of anything. What the public court filings establish is a pattern of conduct that multiple independent plaintiffs, in multiple states, have described in consistent terms. Patterns in court filings are not proof, but they are evidence worth taking seriously.
The treatments at the centre of this - PRP and bone marrow concentrate for joint pain, are not illegal. They are not FDA-approved for these uses. They occupy a regulatory grey zone where physician discretion permits the procedures while the marketing has run well ahead of the evidence. What the lawsuits allege is that this gap was not disclosed.
Patients were shown imagery of doctors in white coats, anatomical diagrams, and medical language designed to signal clinical legitimacy. They were offered payment plans and seasonal discounts. They were told, in some cases, that declining treatment that day would cost them the promotional pricing. None of this is standard medical practice. It is documented sales technique wearing clinical clothes.
The broader question is structural. A clinic chain at this scale is not a rogue operator on the fringes of the field. It is a business model, and the regenerative medicine market has produced several versions of it. The litigation currently underway may clarify whether that model is legally sustainable. It will not, by itself, resolve the regulatory gap that made the model possible.
STUDY OF THE WEEK
What the evidence actually shows for PRP in knee osteoarthritis
Cochrane systematic review - Platelet-Rich Plasma for Osteoarthritis, multiple updates through 2023
Cochrane reviews synthesise the available randomised controlled trial evidence on a given treatment and rate its quality. The review on PRP for knee osteoarthritis - one of the most common conditions marketed by private regenerative clinics - is among the more closely watched in the field.
Study type: Systematic review of randomised controlled trials, human patients.
What they found: Some evidence of modest short-term pain reduction compared to placebo or other injections. Evidence quality rated low to moderate across most outcomes. No consensus on whether the reduction meets the threshold for clinical significance - meaning a benefit the patient would notice in daily life.
Most important caveat: The trials reviewed varied considerably in PRP preparation methods, dosing, and patient selection. This makes it difficult to draw conclusions applicable to any specific clinic's protocol. No FDA approval exists for PRP in osteoarthritis.
Why it matters anyway: This is the independent evidence base for one of the most commercially promoted regenerative treatments in the world. Low-to-moderate certainty of modest short-term benefit is not nothing. It is also not what the marketing says.
WHAT'S REAL / WHAT'S NOISE / WHAT TO WATCH
REAL
Bone marrow transplantation for blood cancers and blood disorders - the benchmark established in Issues 3 and 5, and unchanged. If a haematologist is recommending this for a relevant diagnosis, the evidence is behind them. This is what decades of clinical work looks like when it reaches patients through a regulated pathway.
NOISE
Noise PRP and bone marrow concentrate injections marketed by private clinic chains for joint pain, arthritis, and chronic conditions, without disclosure of FDA approval status. The commercial packaging - clinical imagery, professional language, financing on the spot - is designed to read as medical care. The regulatory status is not.
WATCH
South Korea's clinical-grade iPSC cell bank, now distributing to research institutions. The first government to make this infrastructure publicly available. If the model works and spreads, it reduces one of the significant cost barriers to legitimate iPSC clinical development. Worth following as a structural development in the field, not a clinical one.
THE RED FLAG REPORT
The consultation that cannot wait
A specific pattern appears in the litigation against large-scale regenerative clinic chains, and it is worth knowing before you walk into a consultation anywhere.
The appointment begins with a review of your symptoms. It escalates to a recommendation that covers more of your body than you came in about. A price is presented. Financing is available immediately, through a third party, at terms that sound manageable in the room. You are told the promotional pricing is time-limited. The paperwork is ready.
This is a sales close. It has borrowed the setting and language of a medical consultation, but the structure of it - urgency, upsell, immediate financing, time pressure - is not clinical practice. It is retail technique applied to a medical context.
Any clinic that presents a treatment plan and a financing agreement at the same appointment, before any diagnostic imaging or independent review, is asking you to make a significant financial decision under conditions designed to prevent you from thinking it through. That is the flag. Leave. Think. Come back with questions, or do not come back at all.
READER LENS
"FDA-cleared" and "FDA-approved" are not the same thing
Some clinics use these phrases interchangeably. They are not interchangeable, and the difference is significant.
FDA-approved means the agency has reviewed clinical trial evidence demonstrating that a specific treatment is safe and effective for a specific indication in a specific patient population. This is the standard that Ryoncil met after years of clinical work and two rejected submissions.
FDA-cleared applies to medical devices through a separate pathway called 510(k). It means a device is substantially similar to one already on the market. It says nothing about whether the treatment delivered by that device works for any given condition. A clinic saying its equipment is FDA-cleared is describing a device classification. It is not a statement about treatment efficacy.
When a clinic invokes FDA language in its marketing, ask specifically: is this treatment FDA-approved for my condition? The answer, in most private regenerative medicine clinic contexts, is no. That is a fact the patient is entitled to know before signing anything.
The 87-year-old plaintiff went in with knee pain. She left with a financing agreement covering both hips and both shoulders. The clinic's position is that this was medicine. The court will decide whether it was. Somewhere between those two positions are thousands of other patients who signed and left and have no case pending, and no way to know which side of that line they were on.
